To treat or not to treat: Predicting Asthma Patient' Responsiveness to Omalizumab Using Machine Learning
Résumé
Not being well controlled by therapy with inhaled corticosteroids and long-acting β2 agonist bronchodilators is a major concern for severe-asthma patients. The current treatment option for these patients is the use of biologicals such as anti-IgE treatment, omalizumab, as an add-on therapy. Despite the accepted use of omalizumab, patients do not always benefit from it. Therefore, there is a need to identify reliable biomarkers as predictors of omalizumab response.
| Origine | Fichiers produits par l'(les) auteur(s) |
|---|
